RBC Capital increased Jazz Pharmaceuticals' price target to $179 and maintains an Outperform rating, citing zanidatamab as a key driver of their oncology portfolio.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
RBC Capital increased Jazz Pharmaceuticals' price target to $179 and maintains an Outperform rating, citing zanidatamab as a key driver of their oncology portfolio.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.